Amgen (AMGN) investor relations material

Financial and operational highlights

• Achieved 6% year-over-year revenue growth and 4% product sales growth in Q1, with non-GAAP EPS up 5%.

• Six key growth drivers accounted for nearly 70% of product sales, growing at 24% in Q1.

• 16 products delivered double-digit sales growth; 17 products annualized at $1B+ in Q1.

• Announced an additional $300M investment in Puerto Rico, building on a prior $650M commitment.

• Maintaining financial discipline while investing for long-term growth.

Product portfolio and commercial strategy

• Repatha sales grew 34% year-over-year, driven by strong volume and increased urgency in both secondary and high-risk primary prevention.

• Repatha is widely accessible, with most patients paying under $50/month and virtually no prior authorizations.

• UPLIZNA uptake is split evenly between biologically experienced and naive patients, with convenience and efficacy as key differentiators.

• Commercial resources are dynamically allocated to meet prescriber and patient needs globally.

• Innovative oncology and rare disease portfolios each grew 25% year-over-year, with BiTE medicines and biosimilars as major contributors.

Pipeline and R&D updates

• MariTide, a GIP antagonist/GLP-1 agonist, is advancing in phase III for obesity and diabetes, with potential for less frequent dosing (every 4–12 weeks).

• MariTide shows strong tolerability at target dose and aims to improve patient persistence with less frequent injections.

• Maintenance studies for MariTide will last about a year, with high expected patient participation.

• Olpasiran, an Lp(a)-lowering agent, is in phase III; expected to be more potent than competitors, with a large addressable market.

• UPLIZNA is being developed for additional indications, including autoimmune hepatitis and CIDP, with more phase III studies starting this year.